In the Interests of Patients, Roche Will Consider all Options Following CHMP Opinion on Tarceva in Pancreatic Cancer
Basel, Switzerland (ots/PRNewswire) - Roche announced today that its cancer medicine Tarceva (erlotinib) has received a negative opinion from the European Committee for Medicinal Products for Human Use (CHMP) for use in combination with gemcitabine chemotherapy for the first line treatment of advanced pancreatic ...